Clinical trial · Interventional
68Ga-C1 PET/ CT Imaging in Clear Cell Renal Cell Carcinoma
Evaluation of Diagnostic Value of 68Ga-C1 PET/ CT Imaging in Clear Cell Renal Cell Carcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this clinical trial is to evaluate the diagnostic value of CAIX protein specific probe 68Ga-C1 in PET/CT imaging in clear cell renal cell carcinoma patients. It will also learn about the safety, tolerability and radiation dosimetry of 68Ga-C1. Researchers will compare the diagnostic value of 68Ga-C1 PET/CT and 18F-FDG PET/CT in Chinese patients with indeterminate renal masses or confirmed clear cell renal cell carcinoma.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carbonic Anhydrase IX | — | UNRESOLVED | — |
| Clear Cell Renal Cell Carcinoma | Clear Cell Renal Cell Carcinoma | ONTOLOGY_EXACT | 0.98 |
| PET-CT | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 68Ga-C1 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 68Ga-C1
- description
- Subjects with suspected or confirmed clear cell renal cell carcinoma will receive an intravenous injection of 68Ga-C1 followed by PET imaging. The subjects will also receive a whole-body 18F-FDG PET/CT scan within a one-week period.
- interventionNames
- Drug: 68Ga-C1
Primary outcomes (2)
- measure
- The diagnostic efficacy of 68Ga-C1 PET/CT in the evaluation of clear cell renal cell carcinoma
- timeFrame
- 1 year
- description
- Compare the standardized Uptake Value (SUV) of lesions on 68Ga-C1 and 18F-FDG PET/CT
- measure
- The diagnostic efficacy of 68Ga-C1 PET/CT in the evaluation of malignant tumors
- timeFrame
- 1 year
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Signed written informed consent； 2. Age ≥18； 3. Patients with confirmed or suspected clear cell renal cell carcinoma; 4. Expected survival ≥6 months. Exclusion Criteria: 1. Renal mass is known to be a metastasis of another primary tumor; 2. Have other malignancies that require treatment; 3. Have received chemotherapy, radiotherapy, or immunotherapy within 4 weeks; 4. Renal insufficiency with glomerular filtration rate (GFR) ≤ 60 mL/min/1.73 m²; 5. Pregnant and lactating women or female patients plan to become pregnant within 6 months; 6. Uncontrolled psychiatric disorders; 7. Vulnerable population (e.g., being in detention) or have a serious non-malignant disease (e.g., infectious disease, autoimmune disease, or metabolic disease).
References
Publications (0)
Data not yet available